Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment.
Volkova M, Russell R. · 2011
Read Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. by Volkova M, Russell R. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3322439.txt.
Introduction
Volkova and Russell reviewed heart damage caused by a powerful family of cancer drugs, in a 2011 article. The drugs, called anthracyclines, include doxorubicin and remain mainstays against leukemias, lymphomas, and many solid tumors. Their usefulness is capped by harm to the heart that grows with total dose and can end in irreversible heart failure.
The review explains how the drugs injure heart muscle, how often the damage occurs, and which patients face the highest risk. It surveys ways to catch injury early, including heart imaging and blood markers, before symptoms appear. Prevention options include limiting total dose, spreading doses out, using protective companion drugs, and choosing gentler drug versions. Treatment of established damage follows standard heart failure care, and the authors stress that cancer doctors and heart doctors must plan together.
Catalog record
| CREATOR | Volkova M, Russell R. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment By Maria Volkova, Raymond Russell Published in: Current Cardiology Reviews DOI: 10.2174/157340311799960645 ABSTRACT Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition. INTRODUCTION Cancer chemotherapy has made remarkable advances in the treatment of both solid and hematologic malignancies, allowing in many patients the hope for a cure of their cancer. However, these therapies are not without their complications. In this review, we will address the cardiac toxicity of one of the most common classes of chemotherapeutic agents, the anthracyclines, focusing on the prevalence, diagnosis, treatment and prevention of the cardiotoxicity that should be understood by the cardiologist. PREVALENCE OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY The family of anthracycline drugs originated in the 1950’s with the identification of daunorubicin from the soil bacterium Streptomyces peucetius [1]. In the 1960’s, daunorubicin was found to be quite effective in treating leukemias and lymphomas [2]. Also in the 1960’s, a derivative of daunorubicin, 14-hydroxydaunomycin or Adriamycin (later to be renamed doxorubicin), was identified and shown to be a more effective antitumor agent [3, 4]. Since these initial investigations of this class of antitumor agents, anthracycline chemotherapeutic agents have been employed in the treatment of a wide variety of solid organ tumors and hematologic malignancies, including leukemia, lymphoma, breast cancer, lung cancer, multiple myeloma and sarcoma. Although doxorubicin has become one of the most effective chemotherapeutic agents, it was noted early on that its use was complicated by the development of heart failure [5, 6]. In a retrospective analysis of over 4000 patients receiving doxorubicin performed by Von Hoff and colleagues, 2.2% of the patients developed clinical signs and symptoms of congestive heart failure [6]. Because the study was based on clinician-identified signs and symptoms of congestive heart failure, decreases in left ventricular function without overt symptoms were not identified and the authors acknowledged that “the incidence of drug-induced subclinical left ventricular dysfunction may have been higher”. This study went on to demonstrate that one of the greatest determinants of the development of heart failure is the cumulative dose of doxorubicin, with a sharp increase in the prevalence of heart failure occurring at a cumulative dose of 550 mg/m2. The cumulative dose of anthracycline is a clinical factor that continues through today to predict the development of heart failure. In addition, the use of smaller, divided doses decreased the likelihood of developing heart failure. Subsequent studies measured changes in left ventricular ejection fraction (LVEF) with anthracycline chemotherapy and confirmed a cumulative dose-dependent decrease in LVEF, particularly at cumulative doses of doxorubicin >350 mg/m2 [7, 8]. For the most part, these decreases in left ventricular function were asymptomatic, and if the cardiotoxicity was no more than moderate (a decrease in LVEF of ≥15% to an absolute LVEF between 30 and 45%), stabilization of the LVEF generally occurred with discontinuation of anthracycline therapy. In a retrospective analysis of three trials of doxorubicin treatment of breast cancer or small cell lung cancer (Multicenter trials 088001, 088006 and 088002) in which LVEF was measured by equilibrium radionuclide angiography (ERNA), Swain et al. demonstrated that 5.1% of patients had evidence of congestive heart failure or a significant decline in left ventricular function and confirmed the cumulative dose-dependence of doxorubicin cardiotoxicity [9]. Furthermore, in contrast to previous studies, they demonstrated an increased risk of cardiotoxicity at doses of doxorubicin (≤300 mg/m2) that had previously been considered unlikely to cause left ventricular dysfunction (Table 1). Interestingly, histopathologic changes can be seen in endomyocardial biopsy specimens from patients who have received as little as 240 mg/m2 of doxorubicin [10, 11]. This progressive cardiotoxicity usually occurs after the completion of treatment with anthracyclines, and may become apparent within one year of the completion of treatment (early onset chronic cardiotoxicity) or many years after chemotherapy has been completed (late onset chronic cardiotoxicity). This particular aspect of anthracycline-induced cardiotoxicity is particularly relevant in adult survivors of pediatric malignancies [12, 13]. Up to 65% of patients with a history of a childhood malignancy treated with doxorubicin can have echocardiographic evidence of left ventricular contractile abnormalities [14]. In the Childhood Cancer Survivor Study, a study of 14,358 5-year survivors of childhood malignancies, use of <250 mg/m2 of anthracycline was associated with a 2.4-fold higher risk of developing congestive heart failure compared to those patients who did not receive anthracyclines [13]. This risk increased to 5.2-fold with the use of ≥250 mg/m2 of doxorubicin. In adult patients with breast cancer treated with adjuvant chemotherapy that included anthracyclines, Abu-Khalaf et al. demonstrated that the median absolute change in LVEF from baseline was –5.5% seven years after receiving anthracyclines [15]. Furthermore, 12% of their cohort had an LVEF below the lower limit of normal following chemotherapy. In addition to this late cardiotoxicity, a rare form of acute anthracycline cardiotoxicity has been described in case reports and small patient series [16-18]. The manifestations of this potentially lethal cardiotoxicity may include pericarditis and arrhythmias in addition to left ventricular dysfunction [16, 19]. In contrast to the late cardiotoxicity of anthracyclines, improvement in left ventricular function has been noted to occur in some patients [16, 18]. Furthermore, the mechanism responsible for the acute toxicity may involve an inflammatory response [11], which differs from the generally accepted cause of the chronic anthracycline cardiotoxicity discussed below. A recent case report suggested that treatment with anthracyclines may also produce a stress-induced (takotsubo) cardiomyopathy [20]. MECHANISMS OF CARDIOTOXICITY Chemotherapeutic cardiotoxicity can be characterized as either type 1 or type 2 cardiotoxicity based on the effect of the agent on cardiomyocytes [21]. Type I cardiotoxicity is caused by cardiomyocyte death, either through necrosis or apoptosis, and as a result is not reversible. Type II cardiotoxicity is caused by cardiomyocyte dysfunction rather than cell death and therefore may be reversible. The long-term cardiotoxicity caused by the anthracyclines includes cardiomyocyte death and therefore represents a type I toxicity. Understanding the etiology of this cardiotoxicity has allowed the development of preventive strategies to combat the development of permanent cardiac damage. While the primary mechanisms responsible for the efficacy of doxorubicin in killing rapidly dividing cancer cells are related to DNA damage, the toxicity that doxorubicin exhibits in cardiomyocytes is related to free radical formation caused by doxorubicin metabolism. Specifically, the reduction of doxorubicin by NADH dehydrogenase in mitochondrial respiratory complex I, forms a semiquinone radical that can react with molecular oxygen to form the superoxide radical [22]. Subsequently, redox cycling results in the production of hydrogen peroxide and the hydroxyl radical [23]. In addition, formation of doxorubicin-iron complexes may catalyze a Fenton reaction (Fe2+-catalyzed conversion of hydrogen peroxide to hydroxyl radical) resulting in the generation of reactive oxygen species [24, 25]. It is likely that cardiomyocytes are much more sensitive to the oxidant stress caused by doxorubicin because of their high reliance on oxidative substrate metabolism and therefore the high fraction of cardiomyocyte volume made up by mitochondria compared to glycolytic tumor cells. In fact, oxidant damage by doxorubicin in tumor cells is